SARS-CoV-2 Envelope Protein Fusion Protein

<strong>SARS-CoV-2 Envelope Protein Fusion Protein</strong>_x000D_ <strong>Catalog number:</strong> B2015541_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 25 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 34 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> RT_x000D_ <strong>Keywords:</strong> 2019-nCOV envelope protein Fusion Protein_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Malik YA. Properties of Coronavirus and SARS-CoV-2 Malays J Pathol. 2020 Apr;42(1):3-11._x000D_ 2: Ravi V, Saxena S, Panda PS. Basic virology of SARS-CoV 2 Indian J Med Microbiol. 2022 Apr-Jun;40(2):182-186._x000D_ 3: Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, Roose K, van Schie L; VIB-CMB COVID-19 Response Team; Hoffmann M, P√∂hlmann S, Graham BS, Callewaert N, Schepens B, Saelens X, McLellan JS. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies Cell. 2020 May 28;181(5):1004-1015.e15._x000D_ 4: Aleem A, Akbar Samad AB, Vaqar S. Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19) 2023 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan‚Äì._x000D_ 5: Kordyukova LV, Shanko AV. COVID-19: Myths and Reality Biochemistry (Mosc). 2021 Jul;86(7):800-817._x000D_ 6: SARS-CoV-2 Pseudotyped particle entry SARS-CoV-2 Assays [Internet]. Bethesda (MD): National Center for Advancing Translational Sciences (NCATS); 2020‚Äì._x000D_ 7: Wilkins D, Langedijk AC, Lebbink RJ, Morehouse C, Abram ME, Ahani B, Aksyuk AA, Baraldi E, Brady T, Chen AT, Chi H, Choi EH, Cohen R, Danilenko DM, Gopalakrishnan V, Greenough A, Heikkinen T, Hosoya M, Keller C, Kelly EJ, Kragten-Tabatabaie L, Martin√≥n-Torres F, de Los Santos AHM, Nunes MC, Palomino MA, Papenburg J, Pernica JM, Richmond P, Stein RT, Tuffy KM, Verwey C, Esser MT, Tabor DE, Bont LJ; INFORM-RSV Study Group. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data Lancet Infect Dis. 2023 Jul;23(7):856-866._x000D_ 8: Sanders RW, Moore JP. Virus vaccines: proteins prefer prolines Cell Host Microbe. 2021 Mar 10;29(3):327-333._x000D_ 9: SARS-CoV-2 Pseudotyped particle entry (tox counterscreen) SARS-CoV-2 Assays [Internet]. Bethesda (MD): National Center for Advancing Translational Sciences (NCATS); 2020‚Äì._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/34901700">10: Dahal A, Sonju JJ, Kousoulas KG, Jois SD. Peptides and peptidomimetics as therapeutic agents for Covid-19 Pept Sci (Hoboken). 2022 Jan;114(1):e24245. </a>_x000D_ _x000D_ <strong>Products Related to SARS-CoV-2 Envelope Protein Fusion Protein can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>